Recombinant vaccinia viruses protect against Clostridium perfringens alpha-toxin.
AffiliationDefence Evaluation and Research Agency, Salisbury, Wiltshire, United Kingdom.
MetadataShow full item record
AbstractRecombinant vaccinia viruses that expressed the nontoxic C-domain of Clostridium perfringens alpha-toxin were constructed. The J2R (thymidine kinase [TK] gene) and B13R (serpin 2 [SPI-2] gene) loci were used as insertion sites for the clostridial DNA, and expression of the foreign protein was measured in each case. A double recombinant that encoded the alpha-toxin truncate at the B13R locus and the protective antigen of Bacillus anthracis at the J2R locus was also constructed. Although differences in expression of the alpha-toxin C-domain were recorded, all of the vaccinia recombinants protected mice against a lethal challenge with alpha-toxin demonstrating that a recombinant vaccinia virus can be used to provide protection against a toxin challenge that is known to be solely antibody mediated.
CitationRecombinant vaccinia viruses protect against Clostridium perfringens alpha-toxin. 1999, 12 (2):97-105 Viral Immunol.
- Analysis of protection afforded by a Clostridium perfringens alpha-toxoid against heterologous clostridial phospholipases C.
- Authors: Neeson BN, Clark GC, Atkins HS, Lingard B, Titball RW
- Issue date: 2007 Oct
- [Induced expression of alpha-toxin gene of Clostridium perfringens in recombinant Lactobacillus casei and their immunoprotective in mice].
- Authors: Li X, Xia C, Li Y
- Issue date: 2009 Aug
- Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows.
- Authors: Zeng J, Deng G, Wang J, Zhou J, Liu X, Xie Q, Wang Y
- Issue date: 2011 Jul 26
- A recombinant carboxy-terminal domain of alpha-toxin protects mice against Clostridium perfringens.
- Authors: Nagahama M, Oda M, Kobayashi K, Ochi S, Takagishi T, Shibutani M, Sakurai J
- Issue date: 2013 May
- Naturally occurring Clostridium perfringens nontoxic alpha-toxin variant as a potential vaccine candidate against alpha-toxin-associated diseases.
- Authors: Schoepe H, Pache C, Neubauer A, Potschka H, Schlapp T, Wieler LH, Baljer G
- Issue date: 2001 Nov